Patents by Inventor Amie Strong

Amie Strong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9968666
    Abstract: The present invention is directed to a method for promoting or stimulating a cell-mediated immune response to an antigen, by administering a target antigen (such as a protein) with a transport factor that contains a fragment of a bipartite protein exotoxin, but not the corresponding protective antigen. Preferred transport factors include the protective antigen binding domain of lethal factor (LFn) from B. anthracis, consisting of amino acids 1-255, preferably a fragment of at least 80 amino acids that shows at least 80% homology to LFn, and a fragment of about 105 amino acids from the carboxy portion that does not bind PA. The target antigen can include any molecule for which it would be desirable to elicit a CMI response, including viral antigens and tumor antigens.
    Type: Grant
    Filed: June 11, 2010
    Date of Patent: May 15, 2018
    Assignee: Vaccine Technologies, Incorporated
    Inventors: Yichen Lu, Nicholas Kushner, Amie Strong, Zhenghui Xu
  • Publication number: 20120148621
    Abstract: The present invention is directed to a method for promoting or stimulating a cell-mediated immune response to an antigen, by administering a target antigen (such as a protein) with a transport factor that contains a fragment of a bipartite protein exotoxin, but not the corresponding protective antigen. Preferred transport factors include the protective antigen binding domain of lethal factor (LFn) from B. anthracis, consisting of amino acids 1-255, preferably a fragment of at least 80 amino acids that shows at least 80% homology to LFn, and a fragment of about 105 amino acids from the carboxy portion that does not bind PA. The target antigen can include any molecule for which it would be desirable to elicit a CMI response, including viral antigens and tumor antigens.
    Type: Application
    Filed: June 11, 2010
    Publication date: June 14, 2012
    Applicant: VACCINE TECHNOLOGIES, INCORPORATED
    Inventors: Yichen Lu, Nicholas Kuchner, Amie Strong, Zhenhui Xu